Bangalore, India — (PRESS RELEASE JET) — 09/26/2017 — Synovial Sarcoma – Pipeline Review, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Publisher’s Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 3 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).

– The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 189 pages “Synovial Sarcoma – Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Synovial Sarcoma – Overview, Synovial Sarcoma – Therapeutics Development, Pipeline Overview, Synovial Sarcoma – Therapeutics Assessment, Synovial Sarcoma – Companies Involved in Therapeutics Development, Synovial Sarcoma – Drug Profiles, Synovial Sarcoma – Dormant Projects, Appendix. This report Covered Companies – Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, EpiZyme Inc, Immune Design Corp, Immunocore Ltd, Johnson & Johnson, Karyopharm Therapeutics Inc, Merck & Co Inc, Millennium Pharmaceuticals Inc, Novartis AG, Pfizer Inc, Takara Bio Inc.

For more information Visit at:

Find all Pharma and Healthcare Reports at –

Related Reports;

Polycythemia Vera – Pipeline Review, H2 2017 – Visit at –

Crohn’s Disease (Regional Enteritis) – Pipeline Review, H2 2017 – Visit at –

About is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

Powered by WPeMatico